Gladstone NOW: The Campaign Join Us on the Journey ✕
421 - 435 of 1368 Results Clear All
Nearly 1,000 masks went to unhoused people and evacuees of Sierra Nevada fires
Institutional News Pico
The Conversation—Individuals who survive traumatic brain injury can suffer from life-long complications, such as cognitive deficits, seizures, and sleep disruption. Jeanne Paz, PhD, describes her work in mice showing that treatment with an antibody that blocks an element of immune system activation may be able to prevent such consequences.
Gladstone Experts Traumatic Brain Injury Neurological Disease Paz Lab
abc7 NEWS—Senior Investigator Leor Weinberger, PhD, and Research Investigator Sonali Chaturvedi, PhD, explain their work on a therapy that sharply reduces viral load in the nose of hamsters after a single administration and could add a promising new tool to the therapeutic arsenal against COVID-19.
Gladstone Experts COVID-19 Infectious Disease Weinberger Lab
San Francisco Business Times—Senior Investigator Leor Weinberger, PhD, pioneered a new class of antivirals called therapeutic interfering particles (TIPs), which were recently shown to be effective against SARS-CoV-2 in animal models. The approach is now being developed by a startup company and will be headed to clinical trials.
Gladstone Experts COVID-19 Center for Cell Circuitry Infectious Disease Weinberger Lab
San Francisco Chronicle—The omicron variant of SARS-CoV-2 is spreading rapidly, but it may not be a reason for panic. Nadia Roan explains that our immune system’s cellular response to the vaccines should hold up well against the omicron variant. In addition, Warner Greene predicts that if the variant spreads rapidly but causes just mild disease, it might actually help establish immunity globally, protecting people in places where vaccine access has been limited.
Gladstone Experts COVID-19 Greene Lab Roan Lab
A pioneer of HIV research discusses the last 40 years of HIV/AIDS research and what’s next
HIV/AIDS Greene Lab
Gladstone virologists discuss Omicron and what we might expect in 2022 from the COVID-19 pandemic
Gladstone Experts COVID-19 Greene Lab Ott Lab
Gladstone scientists develop a single-dose intranasal treatment that is effective against variants of the SARS-CoV-2 virus
News Release Research (Publication) COVID-19 Infectious Disease Weinberger Lab Chaturvedi
The method lets researchers more easily study factors that can lead to cell death, in conditions including neurodegenerative diseases
News Release Research (Publication) Center for Systems and Therapeutics
abc7 News—Senior Investigators Warner Greene, MD, PhD, and Nevan Krogan, PhD, discuss the possibility that Omicron, although more transmissible than previous SARS-CoV-2 variants, may cause less severe disease.
Gladstone Experts COVID-19 Center for HIV Cure Research Data Science and Biotechnology Infectious Disease Greene Lab Krogan Lab
Gladstone scientist receives highest distinction for academic inventors
Awards News Release Multiple Sclerosis Alzheimer’s Disease Center for Neurovascular Brain Immunology Akassoglou Lab
San Francisco Chronicle—The identification of an individual infected with the Omicron variant of SARS-CoV-2 in San Francisco is helping local scientists assess the danger posed by the virus. Melanie Ott, director of the Gladstone Institute of Virology, explains that experiments using virus samples from that individual could help determine how well the available vaccines hold up to Omicron’s mutations.
Gladstone Experts COVID-19 Infectious Disease Ott Lab
Gladstone scientists create novel organoids that open new doors for understanding crosstalk between tissues during human development
News Release Research (Publication) Cardiovascular Disease McDevitt Lab Organoids
Researchers at Gladstone Institutes focus on innovative strategies that could finally allow people living with HIV to stop taking daily medications
Gladstone Experts HIV/AIDS Infectious Disease Greene Lab Ott Lab Roan Lab Weinberger Lab Deep Dive
